A Multicenter Study Of The Bruton'S Tyrosine Kinase (Btk) Inhibitor Ibrutinib Plus Durvalumab In Patients With Relapsed/Refractory (R/R) Solid Tumors.David S. Hong,Drew W. Rasco,Michael H. Veeder,Jason J. Luke,Jason Chandler,Ani Sarkis Balmanoukian,Thomas J. George,Pamela Munster,Jordan Berlin,Martin Gutierrez,Alain C. Mita,Heather A. Wakelee,Selda Samakoglu,Shanhong Guan,Isaiah W. Dimery,Erkut BorazanciJOURNAL OF CLINICAL ONCOLOGY（2018）引用 2|浏览45暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
